Synthesis and Dehydrogenation of Spinaceamine and Spinacine 4-Hetaryl Derivatives

N. N. Smolyar, M. G. Abramyants, T. I. Zavyazkina, D. I. Matveeva, Ya. S. Borodkin, and I. A. Voloskii

Litvinenko Institute of Physical Organic and Coal Chemistry, National Academy of Sciences of Ukraine, Donetsk, 83114 Ukraine e-mail: smolyar nik@mail.ru

Received June 10, 2008

Abstract—The reaction of histamine and histidine with various hetarylaldehydes under the conditions of the base-catalyzed Pictet–Spengler process affords 4-hetaryl-substituted derivatives of spinaceamine and spinacine. The dehydrogenation of the 4-hetaryl-substituted spinaceamine derivatives using elemental sulfur in DMF at 120–130°C led to the formation of 4-hetaryl derivatives of imidazo[4,5-*c*]-pyridine. Under similar conditions the 4-hetaryl-substituted spinacine derivatives output derivative decarboxylation resulting in the products identical to the compounds obtained by the dehydrogenation of 4-hetaryl-substituted spinaceamine.

DOI: 10.1134/S1070428009080181

Formerly we described by an example of 4-arylsubstituted spinaceamine and spinacine their dehydrogenation by elemental sulfur in DMF at 120– 150° C. The dehydrogenation of 4-aryl-substituted spinaceamine provided 4-aryl derivatives of imidazo-[4,5-*c*]pyridine, and the 4-aryl-substituted spinacine under the same conditions underwent both aromatization and oxidative decarboxylation giving products identical to those obtained by dehydrogenation of the 4-aryl derivatives of spinaceamine [1].

In extension of the study of these processes in the series of spinaceamine derivatives we performed the dehydrogenation of 4-hetaryl-substituted spinaceamines and spinacines aiming at a development of a synthesis of imidazo[4,5-*c*]pyridine 4-hetaryl derivatives that were difficultly available and might be interesting as promising synthons for the preparation of biologically active substances.


The reaction of histamine (I) and histidine (II) with various hetarylaldehydes afforded new hetarylsubstituted spinaceamines IIIa–IIIi and spinacines IVa– IVk containing in the position 4 of the tetrahydropyridine ring pyridine, thiophene, quinoline, pyrazole, furan, pyrrole, indole, and benzimidazole fragments (see the scheme). 4-Hetaryl-substituted spinaceamines **IIIa–IIIi** and spinacines **IVa–IVk** whose yields attained respectively 33–88 and 30–85% are colorless substances purified by crystallization from water. Their composition and structure were proved by elemental analysis and ¹H NMR spectra.

The heating of 4-hetarylspinaceamines **IIIa–IIIg** in DMF with elemental sulfur at 120–130°C for 2–7 h (till the end of hydrogen sulfide evolution) resulted in 4-hetaryl-substituted imidazo-[4,5-*c*]pyridines **Va–Vg** in 51–61% yields. In the ¹H NMR spectra of these compounds alongside the signals of the imidazole proton H² (7.81–8.78 ppm) and of the protons from the hetaryl fragment signals were present from protons H⁶ (7.87–9.89) and H⁷ (7.33–8.61 ppm) of the pyridine ring with a coupling constant of 5.3–8.0 Hz.

In contrast to spinaceamines **IIIa–IIIg** compounds **IIIh** and **IIIi** containing in the position 4 of the tetrahydropyridine ring pyrrole and furan residues respectively in the course of the dehydrogenation under the chosen conditions suffered decomposition affording tarry products whose structure we failed to establish.

At heating 4-hetarylspinacines **IVa–IVg** under analogous conditions they underwent both aromatization and oxidative decarboxylation giving products identical





Ht = 3-pyridyl (IIIa-Va), 4-pyridyl (IIIb-Vb), 2-thienyl (IIIc-Vc), quinolin-8-yl (IIId-Vd), 1,3-dimethyl-2-oxobenzimidazol-5-yl (IIIe-Ve), 1-phenyl-3-methylpyrazol-4-yl (IIIf-Vf), 1,3-diphenylpyrazol-4-yl (IIIg-Vg), N-methylpyrrol-2-yl (IIIh), 5-methyl-2-furyl (IIIi), 1,3,5-trimethylpyrazol-4-yl (IVh), N-methylpyrrol-2-yl (IVi), N-methylpindol-3-yl (IVj), N-benzylindol-3-yl (IVk).

to compounds **Va–Vg** obtained previously by dehydrogenation of spinaceamines **IIIa–IIIg**. 4-Hetarylsubstituted imidazo[4,5-*c*]pyridines **Va–Vg** formed at the dehydrogenation with sulfur of spinaceamines **IIIa–IIIg** and spinacines **IVa–IVg** have similar melting points and ¹H NMR spectra.

The attempts at the dehydrogenation under similar conditions of spinacines **IVh–IVk** containing in the position 4 of the tetrahydropyridine ring 1,3,5-trimethylpyrazole, pyrrole, and indole fragments led to tarry reaction products whose structure we failed to establish.

Hence the results obtained suggest a conclusion that a new simple method was developed for the synthesis of 4-hetarylimidazo[4,5-*c*]pyridines **Va–Vg** by the dehydrogenation of 4-hetaryl-substituted spinaceamines **IIIa–IIIg** or spinacines **IVa–IVg** with elemental sulfur in DMF at 120–130°C.

The prepared new derivatives of spinaceamine IIIa– IIIi, spinacine IVa–IVk, and imidazo[4,5-*c*]pyridine Va– Vg may be interesting for pharmacology since among analogous compounds of this series substances have been revealed exhibiting a wide range of biological action [2].

EXPERIMENTAL

¹H NMR spectra of compounds synthesized were registered on a spectrometer Varian Gemini-200 at operating frequency 200 MHz, internal reference HMDS. The purity and homogeneity of the products obtained was checked by TLC on Silufol UV-254 plates (eluents ethanol, chloroform; spots visualization by iodine vapor or under UV irradiation).

Spinaceamines **IIIb** and **IIIc** were obtained by procedures [3] and [4] respectively. Spinacine **IVb** was obtained as described in [5].

Spinaceamine 4-hetaryl derivatives IIIa, IIId – IIIi. To a solution of 10 mmol of histamine dihydrochloride (I) in 20 ml of water were added solutions of 30 mmol of NaOH in 10 ml of water and 10 mmol of an appropriate aldehyde in 40 ml of ethanol. The reaction mixture was heated for 5–7 h on a boiling water bath. On cooling the separated pecipitate was filtered off and recrystallized from water.

4-(3-Pyridyl)spinaceamine (IIIa). Yield 1.46 g (73%), mp 171–173°C. ¹H NMR spectrum CD₃OD), δ , ppm: 3.32 t (2H, 7-CH₂), 3.62 t (2H, 6-CH₂), 5.90 s (1H, H⁴), 7.38–7.73 m (1H, H⁵), 7.85 s (1H, H²), 8.11 d (1H, H^{4'}, *J* 7.2 Hz), 8.55 d (1H, H^{6'}, *J* 7.2 Hz), 8.88 s (1H, H^{2'}). Found, %: C 65.93; H 6.07; N 27.80. C₁₁H₁₂N₄. Calculated, %: C 65.98; H 6.04; N 27.98.

4-(Quinolin-8-yl)spinaceamine (IIId). Yield 1.2 g (48%), mp 97–99°C. ¹H NMR spectrum (CD₃OD), δ , ppm: 2.73 t (2H, 7-CH₂), 2.99 t (2H, 6-CH₂), 6.19 s (1H, H⁴), 7.24 d (1H, H^{7'}, J 7.2 Hz), 7.40–7.53 m (3H, H^{3',5',6'}), 7.79 d (1H, H^{4'}, J 7.2 Hz), 8.09 d (1H, H^{2'}, J 7.2 Hz), 8.80s (1H, H²). Found, %: C 71.82; H 5.67; N 22.19. C₁₅H₁₄N₄. Calculated, %: C 71.98; H 5.64; N 22.39.

4-(1,3-Dimethyl-2-oxobenzimidazol-5-yl)spinaceamine (IIIe). Yield 1.3 g (46%), mp 145–147°C. ¹H NMR spectrum (CD₃OD), δ , ppm: 2.77 t (2H, 7-CH₂), 3.10 t (2H, 6-CH₂), 3.31–3.35 m (6H, 2CH₃), 5.08 s (1H, H⁴), 7.00–7.06 m (3H, H^{4',6',7'}), 7.51 s (1H, H²). Found, %: C 63.54; H 6.07; N 24.60. C₁₅H₁₇N₅O. Calculated, %: C 63.58; H 6.05; N.72.

4-(3-Methyl-1-phenylpyrazol-4-yl)spinaceamine (IIIf). Yield 2.45 g (88%), mp 198–200°C. ¹H NMR spectrum (CD₃COOD), δ , ppm: 2.34 s (3H, CH₃), 3.20 t (2H, 7-CH₂), 3.73 t (2H, 6-CH₂), 6.03 s (1H, H⁴), 7.26–7.64 m (5H, C₆H₅), 8.15 s (1H, H²), 8.68 s (1H, H⁵). Found, %: C 68.68; H 6.18; N 25.00. C₁₆H₁₇N₅. Calculated, %: C 68.79; H.14; N 25.07.

4-(1,3-Diphenylpyrazol-4-yl)spinaceamine (IIIg). Yield 2.39 g (70%), mp 253–255°C. ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.19 t (2H, 7-CH₂), 3.74 t (2H, 6-CH₂), 6.22 s (1H, H⁴), 7.30–7.78 m (10H, 2C₆H₅), 8.37 s (1H, H⁵), 8.69 s (1H, H²). Found, %: C.79; H 5.66; N 20.39. C₂₁H₁₉N₅. Calculated, %: C 73.88; H 5.61; N 20.51.

4-(N-Methylpyrrol-2-yl)spinaceamine (IIIh). Yield 0.67 g (33%), mp 148–150°C. ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.21 s (2H, 7-CH₂), 3.67 s (2H, 6-CH₂), 3.75 s (3H, CH₃), 5.99 s (1H, H⁴), 6.05–6.78 m (3H, H^{3'-5'}), 8.73 s (1H, H²). Found, %: C 65.25; H.06; N 27.59. C₁₁H₁₄N₄. Calculated, %: C 65.32; H 6.98; N 27.70.

4-(5-Methyl-2-furyl)spinaceamine (IIIi). Yield 1.22 g (60%), mp 87–88°C. ¹H NMR spectrum (CD₃COOD), δ , ppm: 2.22 s (3H, CH₃), 3.18 s (2H, 7-CH₂), 3.67 s (2H, 6-CH₂), 6.02 s (1H, H⁴), 6.08 s (1H, H⁴), 6.41 s (1H, H³), 8.64 s (1H, H²). Found, %: C.83; H 6.51; N 20.51. C₁₁H₁₄N₄. Calculated, %: C 65.00; H 6.45; N 20.68.

Spinacine 4-hetaryl derivatives IVa, IVc–IVk. To a solution of 10 mmol L-hustidine hydrochloride monohydrate (**II**) in 20 ml of water were added solutions of 30 mmol of NaOH in 10 ml of water and 10 mmol of an appropriate aldehyde in 40 ml of ethanol. The reaction mixture was heated for 5–7 h on a boiling water bath. Ethanol was distilled off in a vacuum, the residue was cooled and acidified with 6N HCl till pH 4–5. The separated pecipitate was filtered off and recrystallized from water.

4-(3-Pyridyl)spinacine (IVa). Yield 1.24 g (51%), mp 228–230°C (decomp.). ¹H NMR spectrum (DMSO-*d*₆), δ, ppm: 2.98 q (2H, 7-CH₂), 3.85 t (1H, H⁶), 5.31 s

(1H, H⁴), 7.46 q (1H, H⁵), 7.58 s (1H, H²), 7.80 d (1H, H^{4'}, J 8.1 Hz), 8.61 d (1H, H^{6'}, J 8.1 Hz), 8.66 s (1H, H²). Found, %: C 58.97; H 4.99; N 22.91. $C_{12}H_{12}N_4O_2$. Calculated, %: C 59.01; H.95; N 22.93.

4-(2-Thienyl)spinacine (IVc). Yield 2.12 g (85%), mp 200–202°C. ¹H NMR spectrum (CD₃OD), δ , ppm: 3.12 q (2H, 7-CH₂), 4.08 q (1H, H⁶), 5.96 s (1H, H⁴), 7.09 d (1H, H^{3'}, J 5.0 Hz), 7.28 q (1H, H^{4'}), 7.54 d (1H, H^{5'}, J 5.0 Hz), 7.81 s (1H, H²). Found, %: C 52.89; H 4.48; N 16.78; S 12.81. C₁₁H₁₁N₃O₂S. Calculated, %: C 53.00; H 4.45; N 16.86; S 12.86.

4-(Quinolin-8-yl)spinacine (IVd). Yield 1.06 g (36%), mp 178–180°C. ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.66 q (2H, 7-CH₂), 4.41 d (1H, H⁶), 6.69 s (1H, H⁴), 7.55–7.73 m (1H, H⁶), 8.09 d (1H, H⁷, *J* 8.1 Hz), 8.15 d (1H, H^{5'}, *J* 8.1 Hz), 8.22 t (1H, H^{3'}), 8.44 d (1H, H^{4'}, *J* 8.1 Hz), 8.64 s (1H, H²), 8.88 d (1H, H^{2'}, *J* 8.1 Hz). Found, %: C 65.19; H 4.80; N 18.90. C₁₆H₁₄N₄O₂. Calculated, %: C 65.30; H 4.79; N 19.04.

4-(1,3-Dimethyl-2-oxobenzimidazol-5-yl)spinacine (IVe). Yield 2.62 g (80%), mp 253–255°C (decomp.). ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.40 s (3H, CH₃), 3.46 s (3H, CH₃), 3.53 q (2H, 7-CH₂), 3.76 t (1H, H⁶), 4.36 s (1H, H⁴), 7.26 d (1H, H^{6'}, *J* 8.1 Hz), 7.57 d (1H, H^{4'}), 7.75 d (1H, H^{7'}, *J* 8.1 Hz), 8.78 s (1H, H²). Found, %: C 58.59; H 5.21; N 21.32. C₁₆H₁₇N₅O₃. Calculated, %: C 58.70; H 5.24; N 21.40.

4-(3-Methyl-1-phenylpyrazol-4-yl)spinacine (**IVf).** Yield 1.62 g (50%), mp 227–229°C (decomp.). ¹H NMR spectrum (CD₃COOD), δ , ppm: 2.39 s (3H, CH₃), 3.44 q (2H, 7-CH₂), 4.61 t (1H, H⁶), 6.25 s (1H, H⁴), 7.26–7.67 m (5H, C₆H₅), 8.14 s (1H, H²), 8.69 s (1H, H⁵). Found, %: C 62.99; H 5.33; N 21.39. C₁₇H₁₇N₅O₂. Calculated, %: C 63.14; H 5.30; N 21.66.

4-(1,3-Diphenylpyrazol-4-yl)spinacine (IVg). Yield 2.46 g (64%), mp 205–208°C (decomp.). ¹H NMR spectrum (DMSO- d_6), δ , ppm: 2.95 q (2H, 7-CH₂), 3.97 t (1H, H⁶), 5.17 s (1H, H⁴), 7.28–7.90 m (10H, 2C₆H₅), 8.14 s (1H, H⁵), 8.57 s (1H, H²). Found, %: C.54; H 5.00; N 18.02. C₂₂H₁₉N₅O₂. Calculated, %: C 68.56; H 4.97; N 18.17.

4-(1,3,5-Trimethylpyrazol-4-yl)spinacine (IVh). Yield 1.9 g (70%), mp 211–213°C (decomp.). ¹H NMR spectrum (DMSO- d_6), δ , ppm: 1.83 s (3H, CH₃), 1.97 C (3H, CH₃), 3.10 q (2H, 7-CH₂), 3.60 s (3H, CH₃), 4.10 d (1H, H⁶), 5.44 s (1H, H⁴), 7.85 s (1H, H²). Found, %: C 56.64; H 6.30; N 25.42. C₁₃H₁₇N₅O₂. Calculated, %: C 56.71; H 6.23; N.44.

RUSSIAN JOURNAL OF ORGANIC CHEMISTRY Vol. 45 No. 8 2009

4-(*N***-Methylpyrrol-2-yl)spinacine (IVi).** Yield 0.74 g (30%), mp 215–217°C (decomp.). ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.44 q (2H, 7-CH₂), 3.77 s (3H, CH₃), 4.45 d (1H, H⁶), 5.98 s (1H, H⁴), 6.04–6.78 m (3H, H^{3'-5'}), 8.71 s (1H, H²). Found, %: C 58.50; H.71; N 22.66. C₁₂H₁₄N₄O₂. Calculated, %: C 58.52; H 5.73; N 22.75.

4-(N-Methylindol-3-yl)spinacine (IVj). Yield 0.98 g (33%), mp 240–242°C (decomp.). ¹H NMR spectrum (CD₃COOD), δ, ppm: 3.62 q (2H, 7-CH₂), 3.85 s (3H, CH₃), 3.93 d (1H, H⁶), 4.33 s (1H, H⁴), 6.77– 7.49 m (4H, C₆H₄), 7.55 s (1H, H²), 8.71 C (1H, H²). Found, %: C 64.80; H 5.47; N 18.82. C₁₆H₁₆N₄O₂. Bbk@C-λενO, %: C 64.85; H 5.44; N.91.

4-(*N***-Benzylindol-3-yl)spinacine (IVk).** Yield 2.6 g (70%), mp 200–202°C (decomp.). ¹H NMR spectrum (CD₃COOD), δ , ppm: 3.55 q (2H, 7-CH₂), 4.58 t (1H, H⁶), 5.34 s (2H, CH₂C₆H₅), 6.45 s (1H, H⁴), 7.05–7.57 m (9H, C₆H₄, CH₂C₆H₅), 8.50 s (1H, H²), 8.74 s (1H, H²). Found, %: C 70.89; H 5.50; N 14.96. C₂₂H₂₀N₄O₂. Calculated, %: C 70.95; H5.41; N 15.05.

Imidazo[4,5-c]pyridine 4-hetaryl derivatives Va– Vg. a. A mixture of 10 mmol of spinaceamine IIIa–IIIg in 50 ml of DMF and 0.7 g (22 mmol) of elemental sulfur was heated for 2–7 h at 120–130°C till the end of H_2S evolution. Then DMF was distilled off in a vacuum till dryness, and the residue was recrystallized from water.

b. To a solution of 10 mmol of spinacine **IVa–IVg** in 50 ml of DMF was added 0.7 g (22 mmol) of elemental sulfur. The mixture was treated as in procedure *a*.

4-(3-Pyridyl)imidazo[4,5-*c***]pyridine (Va).** *a*. Yield 1.0 g (51%), mp 252–254°C. ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 7.63 t (1H, H⁵), 7.69 d (1H, H⁷, *J* 5.6 Hz), 8.54 d (1H, H⁶, *J* 5.6 Hz), 8.55 s (1H, H²), 8.72 d (1H, H^{4'}, *J* 7.2 Hz), 9.07 d (1H, H^{6'}, *J* 7.2 Hz), 9.94 C (1H, H^{2'}). Found, %: C 67.26; H 4.12; N 28.43. C₁₁H₈N₄. Calculated, %: C 67.33; H 4.11; N 28.56.

b. Yield 1.3 g (67%), mp 253–255°C. Found, %: C 67.24; H 4.13; N 28.47.

4-(4-Pyridyl)imidazo[4,5-*c***]pyridine (Vb).** *a*. Yield 1.18 g (60%), mp 273–275°C. ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 7.60 d (1H, H⁷, *J* 5.3 Hz), 8.43 d (1H, H⁶, *J*5.3Hz), 8.47 s (1H, H²), 8.64 d (2H, H^{2',6'}, *J* 4.5 Hz), 8.65 d (2H, H^{3',5'}, *J* 4.5 Hz). Found, %: C 67.29; H 4.15; N 28.49. C₁₁H₈N₄. Calculated, %: C 67.33; H 4.11; N 28.56. *b*. Yield 1.2 g (61%), mp 273–275°C. Found, %: C 67.23; H 4.13; N 28.49.

4-(2-Thienyl)imidazo[4,5-*c***]pyridine (Vc).** *a*. Yield 1.11 g (55%), mp 198–200°C. ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 7.36 t (1H, H^{4'}), 7.86 d (1H, H⁷, *J* 5.5 Hz), 8.03d (1H, H^{3'}, *J* 4.6 Hz), 8.30 d (1H, H⁶, *J* 5.5 Hz), 8.41 d (1H, H^{5'}, *J* 4.6 Hz), 8.67 s (1H, H²). Found, %: C 59.63; H 3.52; N 20.79; S 15.78. C₁₀H₇N₃S. Calculated, %: C 59.68; H 3.51; N 20.88; S 15.93.

b. Yield 1.76 g (88%), mp 197–199°C. Found, %: C 59.59; H 3.53; N 20.74; S 15.82.

4-(Quinolin-8-yl)imidazo[4,5-*c***]pyridine (Vd).** *a*. Yield 1.5 g (60%), mp >300°C. ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 7.71–7.84 m (1H, H⁶), 7.97 d (1H, H⁷', *J*.5Hz), 8.20–8.27 m (2H, H^{4',5'}), 8.55 d (1H, H⁷, *J*7.6 Hz), 8.76 s (1H, H²), 8.75–9.15 m (2H, H^{2',3'}), 9.86 d (1H, H⁶, *J*7.6 Hz). Found, %: C 73.02; H 4.15; N 22.67. C₁₅H₁₀N₄. Calculated, %: C 73.15; H 4.09; N 22.75.

b. Yield 1.70 g (69%), mp > 300°C. Found, %: C 73.12; H 4.13; N.67.

4-(1,3-Dimethyl-2-oxobenzimidazol-5-yl)imidazo[4,5-c]pyridine (Ve). *a*. Yield 1.70 g (60%), mp 226–228°C. ¹H NMR spectrum (DMSO-*d*₆), δ , ppm: 3.33 s (6H, 2CH₃), 7.30 d (1H, H⁷, *J* 8.0 Hz), 7.84 d (1H, H⁶, *J* 8.0 Hz), 8.35–8.39 m (3H, C₆H₃), 8.78 s (1H, H²). Found, %: C 64.43; H 4.72; N 24.97. C₁₅H₁₃N₅O. Calculated, %: C 64.50; H.69; N 25.08.

b. Yield 1.67 g (63%), mp 226–228°C. Found, %: C 64.41; H 4.72; N 24.98.

4-(3-Methyl-1-phenylpyrazol-4-yl)imidazo[4,5-*c***]-pyridine (Vf).** *a*. Yield 1.68 g (61%), mp 103–105°C. ¹H NMR spectrum (DMSO-*d*₆), δ, ppm: 2.68 s (3H, CH₃), 7.20–7.80 m (6H, C₆H₅, H²), 8.20–8.42 m (2H, H⁷, H⁵), 9.33 d (1H, H⁶). Found, %: C 69.68; H 4.79; N.37. C₁₆H₁₃N₅. Calculated, %: C 69.80; H 4.76; N 25.44.

b. Yield 1.62 g (57%), mp 102–103°C. Found, %: C.79; H 4.81; N 25.33.

4-(1,3-Diphenylpyrazol-4-yl)imidazo[4,5-*c***]pyridine (Vg).** *a***. Yield 2.06 g (63%), mp 175–177°C. ¹H NMR spectrum (DMSO-***d***₆), δ, ppm: 7.30–7.75 m (10H, 2C₆H₅), 7.82–8.00 m (2H, H², H⁵), 8.35 d (1H, H⁷,** *J* **7.5 Hz), 9.17 d (1H, H⁶,** *J* **7.5 Hz). Found, %: C 74.69; H 4.55; N 20.65. C₂₁H₁₅N₅. Calculated, %: C 74.75; H 4.48; N 20.76.**

b. Yield 1.11 g (33%), mp 175–177°C. Found, %: C 74.66; H 4.52; N 20.66.

REFERENCES

- 1. Smolyar, N.N., Abramyants, M.G., and Yutilov, Yu.M., *Zh. Org. Khim.*, 2006, vol. 42, 560.
- Stucky, G.C., Roduit, J.P., and Schmidt, B., *Chimia*, 1997, vol. 51, p. 280; Jiang, B., *Org. Proc. Res. & Develop.*, 1998, vol. 2, p. 425; Yutilov, Yu.M. *Adv. Heterocyclic, Chem.*, 2005, vol. 89, p. 161; Penning, T.D., Chandracumar, N.S., Desai, B.N., Djuric, S.W., Gasiecki, A.F., Malecha, J.W., Miyashiro, J.M., Russell, M.A., Askonas, L.J., Gierse, J.K.,

Harding, E.I., Highkin, M.K., Kachur, J.F., Kim, S.H., Villani-Price, D., Pyla, E.Y., Ghoreishi-Haak, N.S., and Smith, W.G., *Eur. J. Med. Chem.*, 2007, vol. 42, p. 1334.

- 3. Stocker, F.B., Fordice, M.W., Larson, J.K., and Thorstenson, J.H., *J. Org. Chem.*, 1966, vol. 31, p. 2380.
- 4. Vitali, T., Mossini, F., and Bertaccini, G., *Farmaco. Ed. Sci.*, 1965, vol. 20, p. 634.
- 5. Yutilov, Yu.M., Abramyants, M.G., and Smolyar, N.N., *Zh. Org. Khim.*, 2001, vol. 37, p. 129.